When is aspirin appropriate in primary ASCVD prevention? Should ezetimibe be added to maximal statin therapy in T2D? This quiz tests your guideline savvy.
Guidelines on prevention of atherosclerotic cardiovascular disease from the American College of Cardiology/American Heart Association, the American Diabetes Association, and the Endocrine Society provide recommendations for reducing the risk of morbidity and mortality associated with this cluster of metabolic dysfunction.
Test your knowledge of guideline-recommended management with Quiz #2 in our series of 4 on cardiometabolic disease.
•Adults aged 40 to 75 yrs with T2D: Prescribe moderate-intensity statin, regardless of 10-yr ASVD risk.
•Adults aged ≥75 yrs: Consider statin therapy based on clinical assessment and risk vs benefit discussion with physician.
•Consider combination lipid lowering therapy in patients with T2D on maximally tolerated statin therapy who are at increased risk for ASCVD.
•According to the 2019 Endocrine Society guideline, persons aged 40 to 75 yrs with LDL-C ≥ 190 mg/dL should start on high intensity statin therapy. But: rule out secondary causes of hyperlipidemia first.